Neoadjuvant Chemotherapy Therapy News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA ® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral presentation at t...
Source: Johnson and Johnson - September 17, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Mesothelioma Research, COVID Findings Featured at IASLC Conference
This study, performed during the pre-vaccine period of the pandemic, once again demonstrates the importance of vaccination against COVID-19,” said Dr. Susana Cedres, a medical oncologist with Vall d’Hebron Hospital. “Malignant pleural mesothelioma patients are particularly vulnerable to COVID-19.” Cedres said since the subsequent rollout of the COVID-19 vaccines, no positive cases have been attributed to pleural mesothelioma patients at the hospital. The average age of the seven patients was 62. All had the epithelioid histology of mesothelioma and two were receiving oncologic treatment at the time of diagnos...
Source: Asbestos and Mesothelioma News - September 15, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Chemotherapy Induced Immune Microenvironment Changes in TNBC Chemotherapy Induced Immune Microenvironment Changes in TNBC
A better understanding of the impacts of neoadjuvant chemotherapy on the immune microenvironment could have important prognostic implications in triple-negative breast cancer.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 2, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Duke Study Suggests Radiation Does Not Extend Mesothelioma Survival
A dual registry analysis by the esteemed Duke University Medical Center has concluded that adjuvant hemithoracic radiation does not improve survival when combined with aggressive surgery for patients with malignant pleural mesothelioma. Although the U.S. National Comprehensive Cancer Network and the European Society for Medical Oncology recommend the adjuvant radiation – as do many specialists – the Duke research team has challenged the conventional treatment with this report. “The receipt of adjuvant hemithoracic radiation was not associated with improved survival when compared to no radiation,” the authors ...
Source: Asbestos and Mesothelioma News - August 9, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Neoadjuvant Chemoimmunotherapy in Resectable NSCLC Neoadjuvant Chemoimmunotherapy in Resectable NSCLC
Is the use of neoadjuvant immunotherapy combined with chemotherapy a safe and effective therapeutic option for patients with resectable non-small cell lung cancer?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 2, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

FDA Approves Neoadjuvant Pembro for Triple-Negative Breast Cancer FDA Approves Neoadjuvant Pembro for Triple-Negative Breast Cancer
The approval is based on phase 3 trial data showing prolonged event-free survival with the pembrolizumab regimen vs neoadjuvant chemotherapy alone for previously untreated stage II or III TNBC.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 28, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Keytruda (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery
KENILWORTH, N.J.--(BUSINESS WIRE) July 27, 2021 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 27, 2021 Category: Drugs & Pharmacology Source Type: news

Top Abstracts in Locally Advanced NSCLC From ASCO 2021 Top Abstracts in Locally Advanced NSCLC From ASCO 2021
Dr Thomas Stinchcombe discusses key data on locally advanced NSCLC from ASCO 2021, including results of atezolizumab as adjuvant therapy and chemotherapy plus immunotherapy in the neoadjuvant setting.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 29, 2021 Category: Consumer Health News Tags: None ReCAP Source Type: news

For Residual TNBC Post-Chemo, Capecitabine Should Be Offered For Residual TNBC Post-Chemo, Capecitabine Should Be Offered
For high-risk patients with triple-negative breast cancer who have residual disease following neoadjuvant therapy, Dr Kathy Miller says we must accept capecitabine as the standard of care.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 15, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A comp...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Long-Term ERLEADA ® (apalutamide) Patient-Reported Outcomes Data in Metastatic Castration-Sensitive Prostate Cancer Demonstrate Maintenance of Health-Related Quality of Life for Patients
May 26, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced patient-reported outcomes (PRO) data from the pre-specified final analysis of the Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC). The TITAN study previously demonstrated statistically significant improvement in overall survival (OS) after a median follow-up of 44 months in patients receiving ERLEADA® plus androgen deprivation therapy (ADT).1 The new PRO data showed that the addition of ERLEADA® to ADT maintained patients’ health-related quality of life (HRQoL) and ...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves Opdivo (nivolumab) as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients who have Received Neoadjuvant Chemoradiotherapy
PRINCETON, N.J.--(BUSINESS WIRE) May 20, 2021 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo® (nivolumab, injection for intravenous use) for the adjuvant treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 20, 2021 Category: Drugs & Pharmacology Source Type: news

U.S. FDA Approves Opdivo (nivolumab) as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients who have Received Neoadjuvant Chemoradiotherapy
PRINCETON, N.J.--(BUSINESS WIRE) May 20, 2021 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo® (nivolumab, injection for intravenous use) for the adjuvant treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 20, 2021 Category: Drugs & Pharmacology Source Type: news

Impact of Tumor Size on pCR Rates in TNBC After Chemotherapy Impact of Tumor Size on pCR Rates in TNBC After Chemotherapy
What impact might tumor size have on pathological complete response rates in triple negative breast cancer patients receiving neoadjuvant chemotherapy?Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 17, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

BERENICE: Further Evidence of Heart Safety of Dual HER2 Blockade BERENICE: Further Evidence of Heart Safety of Dual HER2 Blockade
Final results were presented at ESMO Breast Cancer 2021 on dual HER2 blockade with pertuzumab and trastuzumab on top of anthracycline-based neoadjuvant chemotherapy for early-stage breast cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 14, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news